JP2005523928A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523928A5
JP2005523928A5 JP2004500769A JP2004500769A JP2005523928A5 JP 2005523928 A5 JP2005523928 A5 JP 2005523928A5 JP 2004500769 A JP2004500769 A JP 2004500769A JP 2004500769 A JP2004500769 A JP 2004500769A JP 2005523928 A5 JP2005523928 A5 JP 2005523928A5
Authority
JP
Japan
Prior art keywords
composition
glaucoma
ctgf
intraocular pressure
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004500769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/012521 external-priority patent/WO2003092584A2/en
Publication of JP2005523928A publication Critical patent/JP2005523928A/ja
Publication of JP2005523928A5 publication Critical patent/JP2005523928A5/ja
Withdrawn legal-status Critical Current

Links

JP2004500769A 2002-04-30 2003-04-18 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤 Withdrawn JP2005523928A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37660602P 2002-04-30 2002-04-30
PCT/US2003/012521 WO2003092584A2 (en) 2002-04-30 2003-04-18 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006035819A Division JP2006131643A (ja) 2002-04-30 2006-02-13 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2010208643A Division JP2010280723A (ja) 2002-04-30 2010-09-16 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤

Publications (2)

Publication Number Publication Date
JP2005523928A JP2005523928A (ja) 2005-08-11
JP2005523928A5 true JP2005523928A5 (enExample) 2006-03-23

Family

ID=29401375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004500769A Withdrawn JP2005523928A (ja) 2002-04-30 2003-04-18 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2006035819A Pending JP2006131643A (ja) 2002-04-30 2006-02-13 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2010208643A Withdrawn JP2010280723A (ja) 2002-04-30 2010-09-16 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006035819A Pending JP2006131643A (ja) 2002-04-30 2006-02-13 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2010208643A Withdrawn JP2010280723A (ja) 2002-04-30 2010-09-16 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤

Country Status (15)

Country Link
US (3) US7351407B2 (enExample)
EP (2) EP1497420A4 (enExample)
JP (3) JP2005523928A (enExample)
KR (1) KR20040104566A (enExample)
CN (1) CN1650001A (enExample)
AR (1) AR039511A1 (enExample)
AU (2) AU2003221762B2 (enExample)
BR (1) BR0309623A (enExample)
CA (1) CA2482789A1 (enExample)
MX (1) MXPA04009471A (enExample)
PL (1) PL378030A1 (enExample)
RU (1) RU2332213C2 (enExample)
TW (1) TWI288640B (enExample)
WO (1) WO2003092584A2 (enExample)
ZA (1) ZA200408021B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
ATE400297T1 (de) 2004-02-11 2008-07-15 Fibrogen Inc Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
AU2005244154C1 (en) 2004-04-28 2010-07-01 Fibrogen, Inc. Treatments for pancreatic cancer
WO2006021817A2 (en) 2004-08-23 2006-03-02 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated introacular pressure by sirnas
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
EP2002841A4 (en) 2006-03-23 2009-04-15 Senju Pharma Co OPHTHALMIC COMPOSITION WITH XANTHANGUMMI AND GLUCOSE
CN101505744A (zh) * 2006-07-25 2009-08-12 爱尔康研究有限公司 用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂
US20080057072A1 (en) * 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
US7807629B1 (en) 2007-06-05 2010-10-05 Alcon Research, Ltd. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
US8173668B1 (en) 2007-06-05 2012-05-08 Alcon Research, Ltd. Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma
RU2392960C1 (ru) * 2008-09-26 2010-06-27 Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) Способ коррекции плотности соединительной ткани
RU2411033C1 (ru) * 2009-05-12 2011-02-10 Государственное образовательное учреждение высшего профессионального образования "Владивостокский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ВГМУ Росздрава) Способ лечения глаукомной оптической нейропатии в пожилом и старом возрасте
CN102666587A (zh) 2009-07-02 2012-09-12 菲布罗根有限公司 用于治疗肌营养不良的方法
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
EA025415B1 (ru) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INNER EYE PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA), CPA DERIVATIVES OR PRODRUGS THEREOF
RU2424796C1 (ru) * 2010-05-12 2011-07-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения токсической оптической нейропатии, вызванной длительным приемом кодеинсодержащих лекарственных средств
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
IN2015DN02699A (enExample) 2012-09-05 2015-09-04 Sylentis Sau
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
WO2015132303A1 (en) 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
US11299537B2 (en) 2015-12-10 2022-04-12 Fibrogen, Inc. Methods for treatment of motor neuron diseases
DE102018107621A1 (de) * 2018-03-29 2019-10-02 Imedos Systems GmbH Vorrichtung und Verfahren zur Untersuchung der metabolischen Autoregulation
KR20190115725A (ko) 2018-04-03 2019-10-14 한국과학기술연구원 찰콘 유도체를 포함하는 시신경 보호용 조성물
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
KR102231354B1 (ko) 2020-05-22 2021-03-24 한국과학기술연구원 찰콘 유도체를 포함하는 시신경 보호용 조성물
IL300724A (en) * 2020-08-21 2023-04-01 Oculotherapy Llc Methods of neuroprotection and its uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906467A (en) * 1988-03-24 1990-03-06 New York Medical College Novel, long-duration treatment for glaucoma
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
RU2128486C1 (ru) * 1997-04-04 1999-04-10 Центр по химии лекарственных средств Антиглаукоматозное средство
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JPH11180895A (ja) * 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6500846B1 (en) * 1998-09-01 2002-12-31 Lg Chemical, Ltd. CDK inhibitors having flavone structure
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
AU2001248365A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
HK1052354A1 (zh) * 2000-08-09 2003-09-11 Agouron Pharmaceuticals, Inc. 吡唑-噻唑化合物，包括它们的药物组分，和他们在抑制细胞周期蛋白依赖性激酶用途的方法
WO2002013812A1 (en) 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases
AU3664102A (en) 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
TWI335221B (en) * 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
KR20040104566A (ko) 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제

Similar Documents

Publication Publication Date Title
JP2005523928A5 (enExample)
Singh et al. Ocular chemical injuries and their management
RU2004134733A (ru) Агенты, которые регулируют, ингибируют или модулируют активность и/или экспрессию факторов роста соединительной ткани (фрст), в качестве уникальных средств для снижения внутриглазного давления и лечения глаукоматозных ретинопатий/оптических невропатий
CA2129287A1 (en) Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension
MX9708043A (es) Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior.
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
RU2324483C2 (ru) Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
WO2009021155A1 (en) Histone deacetylase inhibitors for treating degenerative diseases of the eye
JP5421910B2 (ja) ペプチド誘導体およびそれを含む涙液分泌促進組成物
Dayanir et al. Medical control of intraocular pressure after phacoemulsification
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
Hollands et al. The effect of intracameral carbachol on intraocular pressure after cataract extraction
KR20010040457A (ko) 안약 조성물
Balaram et al. Phacoemulsification in patients after allogeneic bone marrow transplantation
JP4653516B2 (ja) 涙液分泌促進ペプチドおよびその組成物
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
Hong et al. Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
Shin et al. Comparison of long-term incidence of posterior capsular opacification between phacoemulsification and phacotrabeculectomy
DE60000736D1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
RU2285511C2 (ru) Средство для лечения синдрома сухого глаза
Örnek et al. Effect of 1% brinzolamide and 0.5% timolol fixed combination on intraocular pressure after cataract surgery with phacoemulsification
JPH10218792A (ja) アンギオテンシン変換酵素阻害薬を有効成分とする涙液分泌促進および角結膜障害治療剤
JP4697027B2 (ja) 角結膜障害治療剤